Small- and large-scale biosimulation applied to drug discovery and development

Drug Discovery Today

Volumn 7, Issue 20, 2002, Pages

  Musante, C J ^a   Lewis, Annette K ^a   Hall, Kevin ^a  

^a Entelos Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; INSULIN; INTERLEUKIN 5; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANALYSIS; ASTHMA; BIOLOGY; COMPUTER ANALYSIS; DIABETES MELLITUS; DRUG RESEARCH; DYNAMICS; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INSULIN SENSITIVITY; MATHEMATICAL ANALYSIS; MODEL; PARAMETER; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVIEW; SIMULATION; STATISTICAL ANALYSIS; T LYMPHOCYTE; TECHNOLOGY; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ASTHMA; COMPUTER SIMULATION; ELECTROPHYSIOLOGY; GLUCOSE; HEART; HIV-1; HUMANS; MODELS, BIOLOGICAL; PHARMACOLOGY; VIRUS REPLICATION;

EID: 0037107986     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02442-X     Document Type: Review

References (33)

1. Pharma 2005 Silicon Rally: The Race to eR&D (1999) Pricewaterhouse Coopers Report. http://www.pwcglobal.com
2. The Fruits of Genomics (2001) Lehman Brothers and McKinsey & Company Report 30, 34
3. Fikes, B.J. (2000) In silico biology prediction: fortune telling gets sophisticated. Biopeople Winter, 17-23
4. Ho R.L. Biosystems modelling for in silico target validation: challenges to implementation. Emerg. Ther. Targets. 4:2000;699-714.
5. Hall, K. et al. (2002) Biosimulation: dynamic modeling of biological systems. Annu. Rep. Med. Chem. (in press)
6. Noble D., et al. Biological simulations in drug discovery. Drug Discov. Today. 4:1999;10-16.
7. Noble D., Colatsky T.J. A return to rational drug discovery: computer-based models of cells, organs and systems in drug target identification. Emerging Therapeutic Targets. 4:2000;39-49.
8. DeFronzo R.A., et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237:1979;E214-E223.
9. Scheen A.J., et al. How to explore insulin sensitivity in man? Ann. Endocrinol. (Paris). 56:1995;523-530.
10. Bergman R.N., et al. Quantitative estimation of insulin sensitivity. Am. J. Physiol. 236:1979;E667-E677.
11. Bergman R.N. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes. 38:1989;1512-1527.
12. Krempf M., et al. Minimal model for determination of insulin sensitivity: repeatability in control and obese subjects. Diabetes Res. Clin. Pract. 26:1994;145-148.
13. Bergman R.N., et al. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J. Clin. Invest. 79:1987;790-800.
14. Beard J.C., et al. The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values. Diabetes. 35:1986;362-369.
15. Swan J.W., et al. Assessment of insulin sensitivity in man: a comparison of minimal model- and euglycaemic clamp-derived measures in health and heart failure. Clin. Sci. (Lond. 86:1994;317-322.
16. Haffner S.M., et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 22:1999;562-568.
17. Dalla Man C., et al. The oral glucose minimal model: estimation of insulin sensitivity from a meal test. IEEE Trans. Biomed. Eng. 49:2002;419-429.
18. Caumo A., et al. Insulin sensitivity from meal tolerance tests in normal subjects: a minimal model index. J. Clin. Endocrinol. Metab. 85:2000;4396-4402.
19. Vicini P., et al. The hot IVGTT two-compartment minimal model: indexes of glucose effectiveness and insulin sensitivity. Am. J. Physiol. 273:1997;E1024-E1032.
20. Cohen, P.T. (1998) Clinical overview of HIV disease: HIV InSite Knowledge Base Chapter. http://www.ucsf.edu
21. Perelson A.S., et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1996;1582-1586.
22. Perelson A.S. Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2:2002;28-36.
23. Noble D. Modeling the heart - from genes to cells to the whole organ. Science. 295:2002;1678-1682.
24. Winslow R.L., et al. Computational models of the failing myocyte: relating altered gene expression to cellular function. Philos. Trans. R. Soc. Lond. A. 359:2001;1187-1200.
25. Kohl P., et al. Computational modeling of biological systems: tools and visions. Philos. Trans. R. Soc. Lond. A. 358:2000;579-610.
26. Stokes C.L., et al. Computer-based mathematical model of asthma. J. Allergy Clin. Immunol. 103:1999;A980.
27. Stokes C.L., et al. A computer model of chronic asthma with application to clinical studies: example of treatment of exercise-induced asthma. J. Allergy Clin. Immunol. 107:2001;A933.
28. Lewis A.K., et al. The roles of cells and mediators in a computer model of chronic asthma. Int. Arch. Allergy Immunol. 124:2001;282-286.
29. Kung T.T., et al. Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. Am. J. Respir. Cell. Mol. Biol. 13:1995;360-365.
30. Mauser P.J., et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am. J. Respir. Crit. Care Med. 152:1995;467-472.
31. Mauser P.J., et al. Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. Am. Rev. Respir. Dis. 148:1993;1623-1627.
32. Leckie M.J., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 356:2000;2144-2148.
33. Perelson A.S., et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 387:1997;188-191.